Up-regulation of Ago2 expression in gastric carcinoma

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Zhang, Jin ^a   Fan, Xiang Shan ^a   Wang, Cai Xia ^a   Liu, Biao ^a   Li, Qin ^a   Zhou, Xiao Jun ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Ago2; Gastric cancer; HER 2; Immunohistochemical analyses; Tissue microarray

Indexed keywords

ARGONAUTE 2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ARGONAUTE PROTEIN; EIF2C2 PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER MORPHOLOGY; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA; STOMACH EPITHELIUM; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR LOCALIZATION; TUMOR VOLUME; UPREGULATION; CARCINOMA; EPITHELIUM; GENETICS; PATHOLOGY; PROGNOSIS; STOMACH TUMOR;

AGED; ARGONAUTE PROTEINS; CARCINOMA; EPITHELIUM; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; PROGNOSIS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84878894068     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0628-2     Document Type: Article

References (37)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
2. Jing JJ, Liu HY, Hao JK, Wang LN, Wang YP, et al. Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010. World J Gastroenterol. 2012;18(11):1262-9.
3. Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA, et al. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer. 2011;47(2):163-74.
4. Van Wynsberghe PM, Chan SP, Slack FJ, Pasquinelli AE. Analysis of microRNA expression and function. Methods Cell Biol. 2011;106:219-52.
5. Sinkovics JG. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (Review). Int J Oncol. 2012;40(2):305-49.
6. Sandhu S, Garzon R. Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol. 2011; 38(6):781-7.
7. Hui A, How C, Ito E, Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer. 2011;30(11):500.
8. Murray MY, Rushworth SA, MacEwan DJ. MicroRNAs as a new therapeutic target towards leukaemia signalling. Cell Signal. 2012;24(2):363-8.
9. Song MY, Pan KF, Su HJ, Zhang L, Ma JL, et al. Identification of Serum MicroRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS ONE. 2012;7(3):e33608.
10. Wang D, Zhang Z, O'Loughlin E, Lee T, Houel S, et al. Quantitative functions of Argonaute proteins in mammalian development. Genes Dev. 2012;26(7):693-704.
11. O'Carroll D, Mecklenbrauker I, Das PP, Santana A, Koenig U, et al. ASlicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev. 2007;21(16):1999-2004.
12. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, et al. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004;15(2):185-97.
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual (7th ed). New York: Springer; 2010.
14. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457(3):299-307.
15. Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer. 2009;1(9):1.
16. Zhang J, Zhan N, Dong WG. Altered expression of seleniumbinding protein 1 in gastric carcinoma and precursor lesions. Med Oncol. 2011;28(4):951-7.
17. Papaconstantinou I, Karakatsanis A, Gazouli M, Polymeneas G, Voros D. The role of microRNAs in liver cancer. Eur J Gastroenterol Hepatol. 2012;24(3):223-8.
18. Majumder S, Jacob ST. Emerging role of microRNAs in drugresistant breast cancer. Gene Expr. 2011;15(3):141-51.
19. Fassan M, Croce CM, Rugge M. miRNAs in precancerous lesions of the gastrointestinal tract. World J Gastroenterol. 2011;17(48): 5231-9.
20. Schoenberg DR. Mechanisms of endonuclease-mediated mRNA decay. Wiley Interdiscip Rev RNA. 2011;2(4):582-600.
21. Cullen BR. Viruses and microRNAs: RISCy interactions with serious consequences. Genes Dev. 2011;25(18):1881-94.
22. Diederichs S, Haber DA. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell. 2007;131(6):1097-108.
23. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2- containing RNAi enzyme complexes. Cell. 2005;123(4):607-20.
24. Leuschner PJ, Ameres SL, Kueng S, Martinez J. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep. 2006;7(3):314-20.
25. Rand TA, Petersen S, Du F, Wang X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell. 2005; 123(4):621-9.
26. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, et al. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science. 2010;328(5986):1694-8.
27. Yoo NJ, Hur SY, Kim MS, Lee JY, Lee SH. Immunohistochemical analysis of RNA-induced silencing complex-related proteins AGO2 and TNRC6A in prostate and esophageal cancers. APMIS. 2010;118(4):271-6.
28. Li L, Yu C, Gao H, Li Y. Argonaute proteins: Potential biomarkers for human colon cancer. BMC Cancer. 2010;10:38.
29. Chang SS, Smith I, Glazer C, Hennessey P, Califano JA. EIF2C is overexpressed and amplified in head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2010;72:337-43.
30. Sand M, Skrygan M, Georgas D, Arenz C, Gambichler T, et al. Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components Argonaute-1, Argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. Mol Carcinog; 2011.
31. Papachristou DJ, Sklirou E, Corradi D, Grassani C, Kontogeorgakos V, et al. Immunohistochemical analysis of the endoribonucleases Drosha, Dicer and Ago2 in smooth muscle tumours of soft tissues. Histopathology; 2012.
32. Zhang X, Graves P, Zeng Y. Overexpression of human Argonaute2 inhibits cell and tumor growth. Biochim Biophys Acta. 2012;1830(3):2553-61.
33. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353:1652-4.
34. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4:361-70.
35. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463-75.
36. Naoghare PK, Tak YK, Kim MJ, Han E, Song JM. Knock-down of argonaute 2 (AGO2) induces apoptosis in myeloid leukaemia cells and inhibits siRNA-mediated silencing of transfected oncogenes in HEK-293 cells. Basic Clin Pharmacol Toxicol. 2011;109(4):274-82.
37. Cheng N, Li Y, Han ZG. Ago2 promotes tumor metastasis via upregulating FAK expression in hepatocellular carcinoma. Hepatology. 2013;57:1906-18.